Eyenovia, INC.: insider trades · United States · SEC (Form 4)

About Eyenovia, INC.

Eyenovia, Inc. is a U.S.-based ophthalmic technology company listed on the NASDAQ in the United States under the ticker EYEN. Its business is built around the proprietary Optejet® topical ophthalmic medication dispensing platform and a pipeline of drug-device combination products designed to improve the delivery of eye treatments. The company’s core proposition is to administer very small, controlled doses more precisely than conventional eyedrops, with the aim of improving ease of use, reducing dosing variability, and potentially enhancing patient tolerability and outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682639/000141057824000226/eyen-20231231x10k.htm?utm_source=openai)) From a historical perspective, Eyenovia changed its name in 2014 and has since evolved as an ophthalmic-focused development company centered on microdose therapeutics and drug-delivery innovation. SEC filings describe the company as developing the Optejet delivery system both for use with its own therapeutic programs and for potential out-licensing in other indications. The company is organized under U.S. law and is headquartered in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682639/000141057824000226/eyen-20231231x10k.htm?utm_source=openai)) Eyenovia’s product strategy has centered on a small number of key assets. The company has focused on Mydcombi®, a mydriasis product, and on clobetasol propionate ophthalmic suspension intended to reduce pain and inflammation after ocular surgery. It has also pursued MicroPine, a development-stage program for pediatric progressive myopia. However, the company disclosed a negative clinical trial result for MicroPine in November 2024, after which it restructured, reduced expenses, and began exploring strategic alternatives to maximize shareholder value. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682639/000141057825001361/eyen-20250331x10q.htm?utm_source=openai)) In competitive terms, Eyenovia occupies a specialized niche at the intersection of ophthalmic pharmaceuticals and medical-device-enabled delivery. Its differentiation is less about large-scale commercialization and more about platform innovation: Optejet is designed to provide more ergonomic administration, better dose consistency, and a potential licensing pathway beyond the company’s current products. This makes Eyenovia a niche player rather than a broad ophthalmology platform company, but one with a potentially distinctive intellectual-property position if the platform can gain broader adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682639/000141057824000226/eyen-20231231x10k.htm?utm_source=openai)) Geographically, the company is primarily U.S.-centric, both operationally and in terms of market access, with its equity traded on the NASDAQ in the United States. Recent corporate updates also point to significant financial and listing-pressure developments. Eyenovia has paused the national rollout of certain products until additional resources are secured, accelerated development efforts around Optejet, announced a 1-for-80 reverse stock split in 2025, and disclosed Nasdaq listing-compliance issues tied to stockholders’ equity levels. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682639/000141057825001361/eyen-20250331x10q.htm?utm_source=openai)) For French- and English-speaking investors, Eyenovia should be viewed as a high-risk small-cap healthcare story with a proprietary technology angle, limited commercial scale, and a recent history of clinical, financing, and exchange-listing pressure.